 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Natus Medical Incorporated (BABY) designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide.
It offers healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
The companys product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. Its neurology products comprise diagnostic electroencephalography and long-term monitoring products, electrodiagnostic monitoring products, diagnostic polysomnography monitoring products, diagnostic intraoperative monitoring products, and transcranial Doppler products.
The companys newborn care products include hearing screening products to screen the hearing in the newborn; brain injury products to diagnose the severity of brain injury, monitor the effectiveness of drug therapies, detect seizure activity and monitor general neurological status; and thermoregulation products to control the newborn environment, including incubators and warmers.
Its newborn care products also comprise jaundice management products to measure bilirubin levels and treat jaundice; diagnostic hearing assessment products to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages; and balance and mobility systems to diagnose and assist in treating balance disorders.
Shares have formed a bullish "flag" after the company reported its quarterly results on July 23rd. It reported adjusted earnings per share (EPS) of 34 cents in the second quarter of 2015. Adjusted EPS surged 21.4% on a year-over-year basis and surpassed the Consensus Estimate by two cents. Higher share prices are expected for this stock.
52-Weeks Trading Range: $27.00 - $46.98
Entry Point: $44.75
Stop Loss: $42.50
Target Price: $49.25
BABY closed at $39.11
